Armed with its powerful and innovative genetic tuning platform (TEMPO), Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine- expanding their range of application to common and chronic diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/13/25 | $175,000,000 |
Hevolution New Enterprise Associates Regeneron Ventures Yosemite | undisclosed |
